Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

By LabMedica International staff writers
Posted on 21 Oct 2026

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams. More...

Fragmented systems and manual handoffs can slow progress, especially as work moves from research and development to manufacturing. A new system now connects and orchestrates scientific workflows from discovery through manufacturing in a single digital environment.

Revvity, Inc. (Waltham, MA, USA) has launched Signals LabGistics, an AI-first scientific workflow orchestration solution from its Revvity Signals Software business. The solution is designed to connect and coordinate processes, workflows, and tasks from discovery to manufacturing. It is intended for organizations working across pharmaceutical, biotechnology, specialty chemical, and materials science environments.

Signals LabGistics uses AI-powered workflow design to translate natural-language descriptions and standard operating procedures into coordinated scientific workflows. The system provides an orchestration layer that helps connect teams, systems, and processes so workflows can be executed more consistently. By linking real-time data and insights in a single digital environment, the solution is designed to support contextualized decision-making and continuous improvement of scientific processes.

The solution operates within the broader Revvity Signals Software ecosystem and is designed to work with existing laboratory and manufacturing platforms. It is also intended to extend to adjacent systems over time. Multi-tier execution and real-time monitoring capabilities are intended to improve information, sample, and activity flow across independent teams, while helping scientists and managers monitor workflow status, identify emerging bottlenecks, and respond before delays affect broader development timelines.

Signals LabGistics also includes flexible compliance and quality capabilities tailored to industry requirements. These capabilities can support pharmaceutical and biotechnology organizations that need to maintain GxP compliance across connected environments, as well as specialty chemicals and materials science companies seeking to minimize additional regulatory overhead. Signals LabGistics is expected to be available in the United States, Canada, Europe, and Japan in December 2026.

“Scientific innovation is increasingly dependent on the ability to coordinate work across people, systems and stages of development. Our Signals LabGistics offering brings those moving parts together and helps organizations move promising therapies and new products forward with greater speed, consistency and confidence,” said Kevin Willoe, president of Revvity Signals Software.

Related Links
Revvity


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automatic CLIA Analyzer
Shine i6000
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.